In addition to mutations, environmental conditions created by the tissues surrounding tumors (stroma) play a major role in cancer progression. In this issue of the Journal of Clinical Investigation, researchers led by Gregg Semenza at Johns Hopkins University examined the interactions between brea

Researchers at Case Western Reserve University School of Medicine have identified a molecule linked to more aggressive forms of breast cancer - a discovery that could point the way to potential cures. Until this study, the ribonucleic acid (RNA) molecule called miR-181a had never before been tied

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer. The research, led by Jian Jian Li, dire

Cleveland Clinic researchers from the Lerner Research Institute have uncovered two new genes associated with Cowden syndrome (CS) according to a new study, published in the online version of the American Journal of Human Genetics. Cowden syndrome is a difficult-to-recognize, under-diagnosed condit

Previous research has shown that a family of genes, proteins and enzymes called the uPA system (for urokinase plasminogen activator) plays an active role in different facets of cancer's biology, including tumor cell invasion, the spread of metastases, and the growth of a primary tumor. Mesupron® is

Younger women who wait at least 15 years after their first menstrual period to give birth to their first child may reduce their risk of an aggressive form of breast cancer by up to 60 percent, according to a Fred Hutchinson Cancer Research Center study. The findings, by Christopher I. Li, M.D., Ph.D

Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, showed that eribulin demonstrated a trend toward improved overall survival.

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators. Finding multiple mutations instead of just on

New survival data from the Phase III CLEOPATRA study, revealed at the San Antonio Breast Cancer Symposium (SABCS), demonstrate that Perjeta reduces the risk of death by 34% in patients with previously untreated advanced HER2-positive breast cancer, compared with the current gold standard of care - H

One of the most frustrating truths about cancer is that even when a treatment works, it often doesn't work for long because cancer cells find ways to resist. However, researchers reporting studies done in mice in the December 11, 2012, issue of Cancer Cell, a Cell Press publication, may have a way t